An in vitro T cell killing assay to assess new Plasmodium falciparum vaccine candidates

Rhea J. Longley(Walter and Eliza Hall Institute of Medical Research), Hill Avs., A Williams, Alexandra J. Spencer(University of Oxford), Katie Ewer(University of Oxford), Karolis Bauza(Jenner Institute), Matthew G. Cottingham(University of Oxford)

Oxford University Research Archive (ORA) (University of Oxford)

January 1, 2013

Cited by 0

Related Papers

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

|The Lancet|2020|5k

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

|The Lancet|2020|2.6k

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

|The Lancet|2021|1.2k

T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial

|Nature Medicine|2020|643

Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial

|The Lancet|2021|457